The Biological Resources Branch (BRB) is one of the extramural arms of the Developmental Therapeutic Program (DTP) in the Division of Cancer Treatment and Diagnosis (DCTD) at NCI. The BRB supports preclinical and early (e.g. Phase I) clinical studies of biological response modifiers (BRMs) research in the biomedical community through a program of grants and contracts. These studies assess the effects of novel biological agents and explore relationships of biological responses with antitumor activity.
The NCI BRB Program Staff provide oversight of the Biopharmaceutical Development Program (BDP) at the Frederick National Laboratory for Cancer Research (FNLCR). The BDP produces a variety of biopharmaceuticals under current Good Manufacturing Practices (cGMP) for Phase I/II human clinical trials or advanced preclinical animal testing. The BDP is operated under contract by Leidos Biomedical Research, Inc., which provides operations and technical support.
This NCI-sponsored facility stores cytokines, monoclonal antibodies, and other biologic reagents under carefully controlled conditions. The repository provides a uniform supply of high-quality reagents to qualified research investigators at no charge. NCI BRB Program Staff provide oversight on the management of this repository.